Next Phase Newsletter

A venture capital fund headquartered in the US is investing with its first fund, and has invested in 15 portfolio companies to date, with the majority being in the Life Sciences and HealthTech sectors. The firm plans to invest in two-or-three new portfolio companies and make one or two additional follow-on investments. The firm typically makes Pre-Seed, Seed and Series A investments ranging in size from $250K to $1M, and its largest total investment (including follow-ons) in any one company is $3.25M. The firm is preparing to launch its Fund II later in 2024. 
 
The firm invests primarily in the Life Sciences and HealthTech sectors and in a wide range of sub-sectors within those sectors. The firm is sector and subsector agnostic and is open to evaluating different types of technologies. 
 
The firm invests in companies with growth-minded founders with proven track records, defensible market positions, and the ability to be positive cash-flow within 12-24 months. The firm is minority-owned and is committed to managing a diverse portfolio of companies with the potential to deliver above-average returns, including companies with minority, female and SEDI founders. The firm is an active investor that can provide valuable de-risking strategic and operational guidance and support through its venture studio, which helps portfolio companies reduce the risk of costly mistakes, get to market sooner and scale faster. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital arm of a large insurance company based in China was injected initially with RMB 1 billion (USD 160 million) to invest in start-ups and early stage companies. The firm is currently raising a RMB 300 million healthcare dedicated fund that will invest in Chinese companies, generally in seed and series A rounds. The firm also manages a USD 100 million fund that invests in overseas companies. The fund is sector agnostic and is interested in healthcare companies. The fund targets relatively mature companies, generally investing in series C and D rounds and allocating USD 5-10 million per company. The fund will target companies with products that address a large market in China or could be strategically beneficial to the insurance company. The firm is actively seeking new investment opportunities in China and especially in the US and Europe. 
 
In healthcare, the firm is seeking to invest in medical devices, diagnostics, and HCIT, especially in digital health. The firm targets products that are consumer-oriented. The firm is opportunistic in terms of subsectors and indications, having said that, the firm typically looks for indications that address a large market in China. For Chinese companies, the firm looks for products in earlier stages of development. For foreign companies, the firm prefers products that have regulatory approval in the US or EU and is ready for CFDA. However, the firm will also consider products in late stage of development or on the verge of regulatory approval. 
 
The firm invests in companies in China and overseas. The firm generally takes an active approach and seeks board of directors representation for Chinese companies. The firm generally takes a relatively passive approach for foreign companies and looks to utilize its connections with hospitals in China to help foreign companies enter and expand in China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A life sciences investment firm has a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. The firm’s investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of the firm’s partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. The firm has no set number of allocations that it plans to make, but is actively reviewing new opportunities from around the globe. The firm has a history of strategic relationships with other venture capital firms or funds targeting specific sectors or geographies within the life sciences.  These working relationships help give the firm a global footprint and vastly expand their deal flow. 
 
The firm’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development. The firm’s funds have invested in over 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, digital health, nutrition, and agribusiness. 
 
The firm seeks to invest its capital in life sciences companies where our operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997, delivering attractive returns to their investors. Effective management is critical to the success of our portfolio companies. The firm assists their portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. The firm develops close working relationships with our management teams to establish ourselves as true partners in business building. The firm strongly prefers board representation, and have received a board seat with 90% of their portfolio companies (based on invested capital). The firm believes this commitment of intellectual capital increases the likelihood of positive outcomes for our investments, and has established them as a preferred partner in the industry. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare, including AI in healthcare and medical devices. The firm manages 3 funds right now, and the latest fund closed in 2022. The firm typically invests $1M-$2M initial check per company,  and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies. 
 
The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage. 
 
The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A leading alternative asset manager in Europe – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, the firm counts on 210 active companies, 64 exits and more than €1,2bn of assets under management. Some of the firm’s portfolio companies have been acquired by multinationals such as Intel, Symantec, IBM, and Facebook, whilst others are listed in public markets such as NASDAQ, the Spanish BME Growth, AIM London, and Euronext Growth. 
 
In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. Outside of Therapeutics, the firm invests in companies that are revenue positive. Ticket sizes range from 1-5M€. 
 
In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 15million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. Outside of Spain, the firm seeks to co-invest in rounds led by local top-tier Venture Capital. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm is part of a large investment holding company with over €25 billion in assets under management. The firm actively seeks early-stage investment opportunities in global companies that offer disruptive therapeutic approaches across modalities and disease areas, specifically addressing unmet medical needs. The firm offers evergreen support until key value-added milestones and meaningful impact are achieved. Investment sizes typically range from 1 to 10 million euros, with the capacity for larger follow-on investments in portfolio companies. The firm is open to participation at any stage, with a preference for Seed to Series B rounds. The firm’s willingness to lead or co-invest extends to companies in Spain and Portugal, and the firm also participates as a co-investor globally, with a special focus on the EU.

The firm is a flexible and opportunistic investor that is currently considering disruptive therapeutics companies in areas of unmet need. The firm will look at opportunities of all stages from pre-clinical to phase I/II.

The firm will invest in privately held companies only. The firm seeks companies with a full-time management team with expertise, successful track records would be a plus but is not required. The firm takes a board seat in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A private equity fund in China mainly focuses pharmaceuticals, medical device & diagnostic, and healthcare services. The firm typically makes equity investments of US$5-10 million per deal over a 5-6 year exit horizon. The firm is open to leading or co-investing. The firm is investing from its RMB and USD funds and is currently seeking opportunities from China and the U.S.

The firm has a clearly defined investment focus primarily on three healthcare subsectors: Pharmaceuticals, Medical Device & Diagnostic, and Medical Service. Within pharmaceuticals, the firm considers chemical drugs in Oncology, Cardiovascular, Gastrointestinal, second generation drugs, brand generics, OTC, drug delivery platforms, CRO/CMO; biotech products in Biosimilar, Vaccines, blood product, etc.; and Traditional Chinese Medicine (TCM). The firm prefers first-in-class projects in phase I or IIa with safety and efficacy data. Within Medical Device and Diagnostics, the firm is interested in High-end devices, Consumables, Implantable Devices and Interventional Devices with high-technical barrier, Molecular Diagnostics, Immunological Diagnostics, and Genetic Diagnostics. The firm is especially interested in medical robotics and AI. In addition, the firm would consider R&D services that support cell therapy, stem cell, and new therapies. For 505b2 drugs or medical devices, the firm considers from preclinical to pre-IND stages.

The firm is looking for experienced management teams with sector expertise. Within China, the firm prefers companies with approved products and sales track record. Within the U.S., the firm can consider earlier stage companies depending on the business model and exit strategy. The firm’s GP has a strong network in China and can offer assistance in distribution and registration. For therapeutics, the firm prefers companies who have completed Phase 1 and Phase 2a trials and can show some safety and efficacy data.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.